Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SR-A1 antibody is a research-use-only antibody that targets class A1 scavenger receptor (SR-A1, also known as SCARA1, MSR1, or CD204). SR-A1 is a pattern recognition receptor primarily expressed on the surface of macrophages, monocytes, dendritic cells, and microglia. In preclinical research, blocking SR-A1 with an antibody has been shown to modulate macrophage polarization (promoting anti-inflammatory M2 polarization) and attenuate inflammatory responses, such as in murine models of dextran sulfate sodium (DSS)-induced colitis, by inhibiting the TLR4-MyD88-NF-kB signaling pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SR-A1 antibody.